Your browser doesn't support javascript.
loading
Ibrutinib-Related Uveitis: A Case Series from Two Tertiary Centres in the United Kingdom.
Ibrahim, Hagar; Chean, Chung Shen; Kalakonda, Anita J M; Kwan, Jennifer; Kumar, Periyasamy; Williams, Stella; Beare, Nicholas A V.
Afiliación
  • Ibrahim H; St Paul's Eye Unit, Liverpool University Hospitals NHS Trust, Liverpool, UK.
  • Chean CS; Department of Ophthalmology, University Hospitals of Leicester NHS Trust, Leicester, UK.
  • Kalakonda AJM; Department of Haematology and Oncology, Clatterbridge Cancer Centre NHS Trust, Liverpool, UK.
  • Kwan J; National Institute for Health and Care Research (NIHR): CRN North West Coast, Liverpool, UK.
  • Kumar P; Department of Ophthalmology, University Hospitals of Leicester NHS Trust, Leicester, UK.
  • Williams S; Department of Ophthalmology, University Hospitals of Leicester NHS Trust, Leicester, UK.
  • Beare NAV; Department of Haematology and Oncology, Clatterbridge Cancer Centre NHS Trust, Liverpool, UK.
Ocul Immunol Inflamm ; : 1-6, 2024 Sep 06.
Article en En | MEDLINE | ID: mdl-39241170
ABSTRACT

PURPOSE:

Ibrutinib is an irreversible Bruton's tyrosine kinase inhibitor that disrupts B-cell receptor signalling. It is licensed for treatment of low-grade B-cell malignancies, including chronic lymphocytic leukaemia, mantle cell lymphoma and lymphoplasmacytic lymphoma. A few case reports in the literature suggest that uveitis may be a side effect of ibrutinib treatment. A strong association between ibrutinib and uveitis is yet to be established in significant numbers.

METHODS:

The study is a retrospective case series, reporting cases of uveitis associated with ibrutinib from two tertiary centres in the United Kingdom Liverpool University Hospitals NHS Foundation Trust and University Hospitals of Leicester NHS Trust.

RESULTS:

The study reports eight cases presenting over a four year period, with mean age of 66.8 years. Onset of uveitis was between 9 and 48 (median 14) months from commencing ibrutinib, categorising it as a Type D or delayed drug reaction. Cases included unilateral and bilateral; anterior, intermediate, posterior and panuveitis. There was an association with cystoid macular oedema or disc swelling. Severity varied from mild, to severe and vision threatening. Presenting visual acuity ranged from 6/9 to 6/60. In all eight cases, uveitis resolved after ibrutinib cessation. In two cases, reintroducing ibrutinib caused uveitis recurrence.

CONCLUSION:

Our case series provides evidence suggestive of a connection between ibrutinib and development of uveitis. Ibrutinib related uveitis appears to be more common than previously recognised. Ibrutinib cessation, if appropriate, appears to be the definitive management. Patients with ibrutinib-related uveitis benefit from multidisciplinary management involving communication between ophthalmologist and haemato-oncologist.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Ocul Immunol Inflamm Asunto de la revista: ALERGIA E IMUNOLOGIA / OFTALMOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Ocul Immunol Inflamm Asunto de la revista: ALERGIA E IMUNOLOGIA / OFTALMOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Reino Unido